Stifel Financial’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-14,983
| Closed | -$1.53M | – | 3437 |
|
|
2023
Q2 | $1.53M | Buy |
14,983
+124
| +0.8% | +$11.7K | ﹤0.01% | 1801 |
|
|
2023
Q1 | $1.35M | Buy |
14,859
+4,103
| +38% | +$241K | ﹤0.01% | 1825 |
|
|
2022
Q4 | $409K | Buy |
10,756
+587
| +6% | +$20.2K | ﹤0.01% | 2589 |
|
|
2022
Q3 | $256K | Sell |
10,169
-268
| -3% | -$7.43K | ﹤0.01% | 2822 |
|
|
2022
Q2 | $317K | Sell |
10,437
-147
| -1% | -$4.38K | ﹤0.01% | 2722 |
|
|
2022
Q1 | $347K | Buy |
10,584
+994
| +10% | +$29.5K | ﹤0.01% | 2788 |
|
|
2021
Q4 | $253K | Sell |
9,590
-34,694
| -78% | -$2.68M | ﹤0.01% | 3010 |
|
|
2021
Q3 | $4.46M | Sell |
44,284
-475
| -1% | -$55.7K | 0.01% | 1081 |
|
|
2021
Q2 | $6.33M | Buy |
44,759
+2,684
| +6% | +$303K | 0.01% | 896 |
|
|
2021
Q1 | $4.2M | Buy |
42,075
+3,152
| +8% | +$368K | 0.01% | 1052 |
|
|
2020
Q4 | $4.81M | Buy |
38,923
+8,402
| +28% | +$1.1M | 0.01% | 898 |
|
|
2020
Q3 | $2.97M | Sell |
30,521
-5,449
| -15% | -$681K | 0.01% | 1014 |
|
|
2020
Q2 | $5.61M | Buy |
35,970
+346
| +1% | +$52.6K | 0.01% | 688 |
|
|
2020
Q1 | $5.13M | Buy |
35,624
+5,158
| +17% | +$996K | 0.01% | 653 |
|
|
2019
Q4 | $6.21M | Sell |
30,466
-606
| -2% | -$111K | 0.01% | 795 |
|
|
2019
Q3 | $2.49M | Buy |
31,072
+519
| +2% | +$44K | 0.01% | 1178 |
|
|
2019
Q2 | $2.88M | Sell |
30,553
-1,432
| -4% | -$124K | 0.01% | 1117 |
|
|
2019
Q1 | $2.75M | Buy |
31,985
+3,356
| +12% | +$279K | 0.01% | 1079 |
|
|
2018
Q4 | $1.61M | Sell |
28,629
-2,649
| -8% | -$162K | 0.01% | 1265 |
|
|
2018
Q3 | $2.55M | Buy |
31,278
+2,492
| +9% | +$176K | 0.01% | 1135 |
|
|
2018
Q2 | $997K | Buy |
28,786
+616
| +2% | +$18.8K | ﹤0.01% | 1617 |
|
|
2018
Q1 | $575K | Buy |
28,170
+20,069
| +248% | +$517K | ﹤0.01% | 1890 |
|
|
2017
Q4 | $229K | Buy |
+8,101
| New | +$226K | ﹤0.01% | 2363 |
|
Other funds holding RETA
Stifel Financial's RETA Position: Q3 2023 in Review
Stifel Financial sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 14,983 shares — an estimated $1.53M sold.
Stifel Financial first reported a position in RETA in Q4 2017 and held it in 23 quarters. The position peaked at $6.33M in Q2 2021. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Stifel Financial reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Stifel Financial sold 14,983 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $1.53M.
- Stifel Financial first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2017 and held it in 23 quarters.
- Stifel Financial's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $6.33M in Q2 2021.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Stifel Financial's 13F filing for Q3 2023, filed 13 Nov 2023.